DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07104539

STRONG-GLP

RecruitingPhase NA

Strength Training Response of Muscle in GLP-1 Users

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

1

Enrollment

30

estimated

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoints

•Lean mass•Balance testing - Percentage of failed recoveries

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07104539
Org study ID25-707

Timeline

Milestones

Study first posted2025-08-05actual
Study start2025-10-08actual
Last update posted2026-01-21actual
Primary completion2026-12estimated (month precision)
Study completion2027-05estimated (month precision)

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age50 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Age, 50y+
•Be taking GLP-1 medicine (Weygovy or Zepbound) for 1 month or less
•Weight <300 lb
•Pass a health and exercise readiness screening

Exclusion criteria

•Age <50
•Weight >300 lb
•Osteoporosis
•Active metabolic, neoplastic, or cardiovascular disease
•Unable or unwilling to provide consent

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
2
Weight & body composition
1

Weight & body composition

1 endpoint
Primary/protocol endpoint

Muscle mass by d3-creatine dilution

Time frame:Water containing creatine isotope consumed in lab; Urine sample collection on Day 0 and Day 3 at baseline and 14 weeks.

Lean mass

change from baseline, improvement

Other clinical outcomes

2 endpoints
Primary/protocol endpoint

Balance testing - Percentage of failed recoveries

Time frame:2-hour testing session in lab at baseline and 14 weeks.

threshold achievement, improvement

Secondary/protocol endpoint

Muscle function

Time frame:500-meter timed walk in lab at baseline and 14 weeks

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.